Sera Prognostics, Inc. (SERA)
| Market Cap | 80.08M -33.2% |
| Revenue (ttm) | 70,000 -35.2% |
| Net Income | -33.23M |
| EPS | -0.66 |
| Shares Out | 39.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,300 |
| Open | 2.070 |
| Previous Close | 2.070 |
| Day's Range | 2.070 - 2.070 |
| 52-Week Range | 1.560 - 3.950 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 5.50 (+170.94%) |
| Est. Earnings | Nov 12, 2026 |
About SERA
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive an... [Read more]
Financial Performance
In 2025, Sera Prognostics's revenue was $81,000, an increase of 5.19% compared to the previous year's $77,000. Losses were -$31.93 million, -2.95% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SERA stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 170.94% from the latest price.
News
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct co...
Sera CFO Austin Aerts to transition out of role, Scott Gleason to succeed
Sera Prognostics (SERA) announced that Scott Gleason has been appointed CFO, effective August 31. Most recently, he served as VP of investor relations and treasury at Neogen Corporation (NEOG). Austin...
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics reports Q2 EPS (18c), consensus (16c)
Reports Q2 revenue $30K, consensus $50K. “During the second quarter, we continued to build momentum across the key drivers of long-term adoption, including payer engagement, policy advancement, clinic...
Sera Prognostics Earnings Call Transcript: Q2 2026
Q2 2026 saw expanded commercial partnerships, a major Medicaid win in Illinois, and strengthened clinical evidence for PreTRM Test-guided care. Revenue grew 76% year-over-year, with a net loss of $9.1 million and a cash runway through 2029. Illinois Medicaid coverage is expected to drive gradual adoption.
Sera Prognostics Earnings release: Q2 2026
Sera Prognostics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Sera Prognostics Quarterly report: Q2 2026
Sera Prognostics has published its Q2 2026 quarterly earnings report on August 12, 2026.
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics Slides: Corporate presentation
Sera Prognostics has posted slides in relation to its latest quarterly earnings report, which was published on August 7, 2026.
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
SALT LAKE CITY, July 29, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics management to meet virtually with Craig-Hallum
Virtual Meeting to be held on July 21 hosted by Craig-Hallum.
Sera Prognostics’ PreTRM Test shows efficacy guiding first-time pregnancy care
Sera Prognostics (SERA) announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM Test-guided care in first-time pregnancies si...
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population -- SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nas...
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
SALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics part of ARPA-H award for birth safety test development
Sera Prognostics (SERA) announced its participation in a multi-institutional research program that was awarded up to $10.4M by the Advanced Research Projects Agency for Health, or ARPA-H, to develop a...
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk-- SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), f...
Sera Prognostics Transcript: AGM 2026
The meeting saw the election of two directors for terms expiring in 2029 and the ratification of Ernst & Young as auditors. Shareholders were given opportunities for questions, and management highlighted risks associated with forward-looking statements.
Craig-Hallum bullish on Sera Prognostics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Sera Prognostics (SERA) with a Buy rating and $6 price target The firm notes Sera has a proprietary test to identify asymptomatic women…
Sera Prognostics initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Sera Prognostics (SERA) with a Buy rating and $6 price target
Sera Prognostics Transcript: Jefferies Global Healthcare Conference 2026
Following strong PRIME study results, investments shifted from clinical to commercial focus, extending cash runway through 2029. Key milestones include reimbursement wins, staged provider rollout, and legislative successes like Illinois Medicaid coverage, with broad awareness seen as the main adoption hurdle.
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
Sera Prognostics Proxy statement: Proxy filing
Sera Prognostics filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Sera Prognostics reports Q1 EPS (17c), consensus (17c)
Reports Q1 revenue $14K, consensus $66.67K. “In Q1, our primary focus was building awareness with clinicians and the broader stakeholder community as we continue the evolution from clinical stage to…
Sera Prognostics Earnings Call Transcript: Q1 2026
Q1 2026 saw continued investment in awareness, advocacy, and commercial expansion, with revenue remaining modest at $14,000 and operating expenses at $9.4 million. Cash runway now extends through 2029, as resource allocation shifts from R&D to commercialization.